These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25125473)

  • 21. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
    Werkström V; Svensson A; Andersson KE; Hedlund P
    BJU Int; 2006 Aug; 98(2):414-23. PubMed ID: 16626307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Phosphodiesterase regulation of cardiovascular functions].
    Li L; He Q; Gao YS
    Sheng Li Ke Xue Jin Zhan; 2010 Apr; 41(2):100-6. PubMed ID: 21416994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.
    Wang ZZ; Zhang Y; Zhang HT; Li YF
    Curr Pharm Des; 2015; 21(3):303-16. PubMed ID: 25159069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
    Andersson KE; Uckert S; Stief C; Hedlund P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
    Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
    J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphodiesterase inhibitors for cognitive enhancement.
    Rose GM; Hopper A; De Vivo M; Tehim A
    Curr Pharm Des; 2005; 11(26):3329-34. PubMed ID: 16250839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
    Kim NN
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.
    Heckman PRA; Blokland A; Prickaerts J
    Adv Neurobiol; 2017; 17():135-168. PubMed ID: 28956332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction.
    Duinen MV; Reneerkens OA; Lambrecht L; Sambeth A; Rutten BP; Os JV; Blokland A; Prickaerts J
    Curr Pharm Des; 2015; 21(26):3813-28. PubMed ID: 26044976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychiatric aspects of phosphodiesterases: An overview.
    Murthy VS; Mangot AG
    Indian J Pharmacol; 2015; 47(6):594-9. PubMed ID: 26729948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations.
    Heckman PRA; Blokland A; Bollen EPP; Prickaerts J
    Neurosci Biobehav Rev; 2018 Apr; 87():233-254. PubMed ID: 29454746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor.
    Deshmukh R; Sharma V; Mehan S; Sharma N; Bedi KL
    Eur J Pharmacol; 2009 Oct; 620(1-3):49-56. PubMed ID: 19699735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterases as therapeutic targets for Huntington's disease.
    Fusco FR; Giampà C
    Curr Pharm Des; 2015; 21(3):365-77. PubMed ID: 25159076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
    Francis SH; Corbin JD
    Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erectile dysfunction and phosphodiesterase type 5 inhibitors].
    Roumeguère T; Sternon J; Schulman CC
    Rev Med Brux; 2003 Jun; 24(3):169-75. PubMed ID: 12891884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.